People in the News


Swift Biosciences said this week that Steve Spotts has joined the company as chief commercial officer.

Prior to joining Swift, Spotts was commercial modality leader for label-free products at GE Healthcare. Prior to that, he was vice president of sales and marketing at MicroCal. Spotts has also served as vice president of sales and marketing, and vice president of marketing at Pharmacia Biotech (now GE Healthcare); and as a management consultant to the life science industry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

Sponsored by

This webinar will discuss a new approach to amplicon sequencing that addresses the current inefficiencies of the method, such as small designs, primer drop outs, and low uniformity.

Sponsored by

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.